[Form 3] Salarius Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Salarius Pharmaceuticals (SLRX) disclosed the equity holdings of its Chief Executive Officer in connection with an event dated 11/12/2025. The CEO beneficially owns 16,666 shares of common stock directly. In addition, he holds Series A Preferred Stock that is convertible into 141,734 shares of common stock, which will automatically convert after stockholder approval and satisfaction of certain Nasdaq listing standards.

The CEO also holds derivative securities, including Series A and Series B warrants each exercisable for 16,666 shares of common stock at an exercise price of $1.5, with expiration dates on 11/12/2030 and 11/12/2026, respectively. He further holds stock options for 5,061 and 8,318 shares of common stock at exercise prices of $4.9369 and $50.2579, with some options exercisable only after stockholder approval and satisfaction of certain Nasdaq listing standards.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

PIERCE FREDERICK II

(Last) (First) (Middle)

2450 HOLCOMBE BLVD STE X

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/12/2025

3. Issuer Name and Ticker or Trading Symbol
Salarius Pharmaceuticals, Inc. [ SLRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Office

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	16,666	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	(1)	Common Stock	50,619	(1)	D
Series A Warrants	11/12/2025	11/12/2030	Common Stock	16,666	$1.5	D
Series B Warrants	11/12/2025	11/12/2026	Common Stock	16,666	$1.5	D
Stock Option (right to buy)	(2)	03/31/2032	Common Stock	5,061	$4.9369	D
Stock Option (right to buy)	(2)	07/15/2030	Common Stock	8,318	$50.2579	I	By: Frederick E. Pierce II Living Trust date January 28, 2011 Pierce

Explanation of Responses:

1. The Series A Preferred Shares are convertible into 141,734 shares of Common Stock. The Series A Preferred Shares have no expiration date, and convert automatically into shares of Common Stock following stockholder approval and satisfaction of certain Nasdaq listing standards.

2. The Stock Options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Remarks:

Exhibit 24, Power of Attorney, is attached.

	/s/Mark Rosenblum, as Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction or holding did Salarius Pharmaceuticals (SLRX) report?

The company reported the equity holdings of its Chief Executive Officer, including common stock, preferred stock convertible into common stock, warrants, and stock options as of an event dated 11/12/2025.

How many shares of Salarius Pharmaceuticals (SLRX) common stock does the CEO directly own?

The CEO directly owns 16,666 shares of Salarius Pharmaceuticals common stock.

What is the conversion feature of the Series A Preferred Stock held by the SLRX CEO?

The CEO’s Series A Preferred Shares are convertible into 141,734 shares of common stock. These preferred shares have no expiration date and convert automatically into common stock following stockholder approval and satisfaction of certain Nasdaq listing standards.

What warrants linked to SLRX common stock does the CEO hold?

The CEO holds Series A Warrants exercisable from 11/12/2025 until 11/12/2030 for 16,666 shares of common stock at an exercise price of $1.5, and Series B Warrants exercisable from 11/12/2025 until 11/12/2026 for another 16,666 shares at the same exercise price of $1.5.

What stock options in SLRX does the CEO hold and when do they expire?

The CEO holds stock options to buy 5,061 shares of common stock at an exercise price of $4.9369 expiring on 03/31/2032, and options to buy 8,318 shares at an exercise price of $50.2579 expiring on 07/15/2030. These options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Is any of the SLRX CEO’s ownership held indirectly?

Yes. Part of the CEO’s equity exposure is held through the Frederick E. Pierce II Living Trust dated January 28, 2011, as noted for one of the stock option positions.